Results
- Showing results for:
- Reset all filters
Search results
-
Journal articlePasculli G, Busan P, Jackson ES, et al., 2024,
Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?
, Front Hum Neurosci, Vol: 18, ISSN: 1662-5161Developmental stuttering (DS) is a neurodevelopmental speech-motor disorder characterized by symptoms such as blocks, repetitions, and prolongations. Persistent DS often has a significant negative impact on quality of life, and interventions for it have limited efficacy. Herein, we briefly review existing research on the neurophysiological underpinnings of DS -specifically, brain metabolic and default mode/social-cognitive networks (DMN/SCN) anomalies- arguing that psychedelic compounds might be considered and investigated (e.g., in randomized clinical trials) for treatment of DS. The neural background of DS is likely to be heterogeneous, and some contribution from genetically determinants of metabolic deficiencies in the basal ganglia and speech-motor cortical regions are thought to play a role in appearance of DS symptoms, which possibly results in a cascade of events contributing to impairments in speech-motor execution. In persistent DS, the difficulties of speech are often linked to a series of associated aspects such as social anxiety and social avoidance. In this context, the SCN and DMN (also influencing a series of fronto-parietal, somato-motor, and attentional networks) may have a role in worsening dysfluencies. Interestingly, brain metabolism and SCN/DMN connectivity can be modified by psychedelics, which have been shown to improve clinical evidence of some psychiatric conditions (e.g., depression, post-traumatic stress disorder, etc.) associated with psychological constructs such as rumination and social anxiety, which also tend to be present in persistent DS. To date, while there have been no controlled trials on the effects of psychedelics in DS, anecdotal evidence suggests that these agents may have beneficial effects on stuttering and its associated characteristics. We suggest that psychedelics warrant investigation in DS.
-
Journal articleDelli Pizzi S, Chiacchiaretta P, Sestieri C, et al., 2023,
LSD-induced changes in the functional connectivity of distinct thalamic nuclei
, NEUROIMAGE, Vol: 283, ISSN: 1053-8119 -
Journal articleSavoldi R, Roazzi A, Escobar JAC, et al., 2023,
The Structural Organization and Construct Validity Evidence of the Brazilian Versions of the Mysticism Scale and the Ego-Dissolution Inventory in a Major Religion of the Ayahuasca
, International Journal of Latin American Religions, Vol: 7, Pages: 521-549Mystical experiences and ego dissolution are essential to understanding the lasting psychological effects of psychedelics or even natural religious experience. The main objective of the article is to present evidence of construct validity in the adaptation to Brazilian Portuguese of the Hood Mysticism Scale (HMS) and the Ego-Dissolution Inventory (EDI)-8 through two psychometric techniques: the smallest space analysis technique and the factorial analysis. Design: a cross-sectional survey. The sample consisted of 1414 members of the União do Vegetal religion. The smallest space analysis (SSA) identified three distinct regions in HMS: introversive mysticism, extroversive mysticism, and interpretation. The SSA for EDI-8 suggests four distinct regions, which were conceptualized as (1) loss of ego, (2) total dissolution, (3) ego quiet, and (4) internal–external unity. In addition, a confirmatory factor analysis (CFA) was used to test the factorial replicability of the HMS and EDI-8. The CFA presented acceptable support for the dimensional structures tested. Conclusion: Results show good reliability and validity indicators, which endorse the Portuguese HMS and EDI-8 application in future research.
-
Journal articleWeiss B, Sleep CE, Beller NM, et al., 2023,
Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model
, JOURNAL OF PSYCHEDELIC STUDIES, Vol: 7, Pages: 200-226 -
Conference paperErritzoe D, 2023,
Keynote Lecture 2 "Psychedelics in mental health - therapeutic potential and possible brain mechanisms"
, 71st International Congress and Annual Meeting of the Society-for-Medicinal-Plant-and-Natural-Product-Research, Publisher: GEORG THIEME VERLAG KG, Pages: 1284-1284, ISSN: 0032-0943 -
Journal articleNutt DJ, 2023,
Pharmacological Dissection of Antipsychotics
, BIOLOGICAL PSYCHIATRY, Vol: 94, Pages: 524-525, ISSN: 0006-3223 -
Journal articleWall MB, Harding R, Zafar R, et al., 2023,
Neuroimaging in psychedelic drug development: past, present, and future
, MOLECULAR PSYCHIATRY, ISSN: 1359-4184 -
Journal articleBremler R, Katati N, Shergill P, et al., 2023,
Case analysis of long-term negative psychological responses to psychedelics
, Scientific Reports, Vol: 13, Pages: 1-15, ISSN: 2045-2322Recent controversies have arisen regarding claims of uncritical positive regard and hype surrounding psychedelic drugs and their therapeutic potential. Criticisms have included that study designs and reporting styles bias positive over negative outcomes. The present study was motivated by a desire to address this alleged bias by intentionally focusing exclusively on negative outcomes, defined as self-perceived ‘negative’ psychological responses lasting for at least 72 h after psychedelic use. A strong justification for this selective focus was that it might improve our ability to capture otherwise missed cases of negative response, enabling us to validate their existence and better examine their nature, as well as possible causes, which could inspire risk-mitigation strategies. Via advertisements posted on social media, individuals were recruited who reported experiencing negative psychological responses to psychedelics (defined as classic psychedelics plus MDMA) lasting for greater than 72 h since using. Volunteers were directed to an online questionnaire requiring quantitative and qualitative input. A key second phase of this study involved reviewing all of the submitted cases, identifying the most severe—e.g., where new psychiatric diagnoses were made or pre-existing symptoms made worse post psychedelic-use—and inviting these individuals to participate in a semi-structured interview with two members of our research team, during which participant experiences and backgrounds were examined in greater depth. Based on the content of these interviews, a brief summary of each case was compiled, and an explorative thematic analysis was used to identify salient and consistent themes and infer common causes. 32 individuals fully completed an onboarding questionnaire (56% male, 53% < age 25); 37.5% of completers had a psychiatric diagnosis that emerged after their psychedelic experience, and anxiety symptoms arose or worsened in 87%.
-
Journal articleGarel N, Drury J, Levesque JT, et al., 2023,
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
, FRONTIERS IN PSYCHIATRY, Vol: 14, ISSN: 1664-0640 -
Journal articleMurphy RJ, Sumner R, Evans W, et al., 2023,
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial
, BIOLOGICAL PSYCHIATRY, Vol: 94, Pages: 511-521, ISSN: 0006-3223- Author Web Link
- Cite
- Citations: 5
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
